NO306096B1 - Fremgangsmåte for fremstilling av et kolonisk tilförselssystem - Google Patents

Fremgangsmåte for fremstilling av et kolonisk tilförselssystem Download PDF

Info

Publication number: NO306096B1
Authority: NO; Norway
Prior art keywords: drug; stated; polymer; colon; indomethacin
Prior art date: 1990-05-04

Application number

NO924227A

Other languages

English (en)

Norwegian (no)

Other versions

NO924227L (no

NO924227D0 (no

Inventor

Amnon Sintov

Abraham Rubinstein

Original Assignee

Perio Prod Ltd

Yissum Res Dev Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-04

Filing date

1992-11-03

Publication date

1999-09-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24065163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306096(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-11-03 Application filed by Perio Prod Ltd, Yissum Res Dev Co filed Critical Perio Prod Ltd

1992-11-03 Publication of NO924227D0 publication Critical patent/NO924227D0/no

1992-12-30 Publication of NO924227L publication Critical patent/NO924227L/no

1999-09-20 Publication of NO306096B1 publication Critical patent/NO306096B1/no

Links

238000012384 transportation and delivery Methods 0.000 title claims abstract description 53
230000000112 colonic effect Effects 0.000 title claims abstract description 47
238000004519 manufacturing process Methods 0.000 title claims description 8
239000003814 drug Substances 0.000 claims abstract description 152
229940079593 drug Drugs 0.000 claims abstract description 151
210000001072 colon Anatomy 0.000 claims abstract description 61
229920000642 polymer Polymers 0.000 claims abstract description 39
239000011159 matrix material Substances 0.000 claims abstract description 31
210000000813 small intestine Anatomy 0.000 claims abstract description 22
150000001720 carbohydrates Chemical class 0.000 claims abstract description 15
210000002784 stomach Anatomy 0.000 claims abstract description 15
239000000126 substance Substances 0.000 claims abstract description 7
230000007515 enzymatic degradation Effects 0.000 claims abstract description 3
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 100
238000000034 method Methods 0.000 claims description 59
229960000905 indomethacin Drugs 0.000 claims description 50
241000894006 Bacteria Species 0.000 claims description 23
229920001542 oligosaccharide Polymers 0.000 claims description 18
150000002482 oligosaccharides Chemical class 0.000 claims description 17
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 14
229920001287 Chondroitin sulfate Polymers 0.000 claims description 14
229940059329 chondroitin sulfate Drugs 0.000 claims description 14
229920005615 natural polymer Polymers 0.000 claims description 13
229920001277 pectin Polymers 0.000 claims description 12
239000001814 pectin Substances 0.000 claims description 11
235000010987 pectin Nutrition 0.000 claims description 11
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 8
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
150000003431 steroids Chemical group 0.000 claims description 7
229920002683 Glycosaminoglycan Polymers 0.000 claims description 6
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
229910052751 metal Inorganic materials 0.000 claims description 6
239000002184 metal Substances 0.000 claims description 6
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 5
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 5
229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
239000002260 anti-inflammatory agent Substances 0.000 claims description 5
239000002246 antineoplastic agent Substances 0.000 claims description 5
125000005395 methacrylic acid group Chemical group 0.000 claims description 5
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 5
229920001059 synthetic polymer Polymers 0.000 claims description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
229940034982 antineoplastic agent Drugs 0.000 claims description 4
229910052791 calcium Inorganic materials 0.000 claims description 4
239000011575 calcium Substances 0.000 claims description 4
229960003957 dexamethasone Drugs 0.000 claims description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
229960000890 hydrocortisone Drugs 0.000 claims description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
108010036949 Cyclosporine Proteins 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
229940092705 beclomethasone Drugs 0.000 claims description 3
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
229960001265 ciclosporin Drugs 0.000 claims description 3
229960004397 cyclophosphamide Drugs 0.000 claims description 3
229930182912 cyclosporin Natural products 0.000 claims description 3
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
229960005420 etoposide Drugs 0.000 claims description 3
229960002714 fluticasone Drugs 0.000 claims description 3
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 3
208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims description 3
229960000201 isosorbide dinitrate Drugs 0.000 claims description 3
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
229960000511 lactulose Drugs 0.000 claims description 3
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 3
229960001428 mercaptopurine Drugs 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
229960001597 nifedipine Drugs 0.000 claims description 3
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
229960001603 tamoxifen Drugs 0.000 claims description 3
229960000278 theophylline Drugs 0.000 claims description 3
CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 claims description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
229940124575 antispasmodic agent Drugs 0.000 claims description 2
229960004436 budesonide Drugs 0.000 claims description 2
239000000812 cholinergic antagonist Substances 0.000 claims description 2
WDURTRGFUGAJHA-MMQBYREUSA-M cimetropium bromide Chemical compound [Br-].C[N+]1([C@@H]2CC(C[C@H]1[C@@H]1O[C@@H]12)OC(=O)[C@@H](CO)C=1C=CC=CC=1)CC1CC1 WDURTRGFUGAJHA-MMQBYREUSA-M 0.000 claims description 2
229960003705 cimetropium bromide Drugs 0.000 claims description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
230000001580 bacterial effect Effects 0.000 abstract description 10
102000004169 proteins and genes Human genes 0.000 abstract description 10
108090000623 proteins and genes Proteins 0.000 abstract description 10
108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
230000008685 targeting Effects 0.000 abstract description 7
102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
208000019399 Colonic disease Diseases 0.000 abstract description 3
230000002255 enzymatic effect Effects 0.000 abstract description 3
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 35
239000000203 mixture Substances 0.000 description 35
241000700159 Rattus Species 0.000 description 33
238000002474 experimental method Methods 0.000 description 33
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 29
239000002953 phosphate buffered saline Substances 0.000 description 29
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
229920002567 Chondroitin Polymers 0.000 description 21
108090000790 Enzymes Proteins 0.000 description 19
102000004190 Enzymes Human genes 0.000 description 19
210000001035 gastrointestinal tract Anatomy 0.000 description 19
239000002609 medium Substances 0.000 description 19
239000000047 product Substances 0.000 description 18
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 14
229960004963 mesalazine Drugs 0.000 description 14
150000001875 compounds Chemical class 0.000 description 13
239000003826 tablet Substances 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
238000004090 dissolution Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
230000015556 catabolic process Effects 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
229940002612 prodrug Drugs 0.000 description 10
239000000651 prodrug Substances 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
230000001186 cumulative effect Effects 0.000 description 9
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 9
229960000907 methylthioninium chloride Drugs 0.000 description 9
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical group C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 9
229960001940 sulfasalazine Drugs 0.000 description 9
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
239000000178 monomer Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
239000012738 dissolution medium Substances 0.000 description 7
238000012377 drug delivery Methods 0.000 description 7
230000000694 effects Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
-1 acetate ester Chemical class 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229930182480 glucuronide Natural products 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
QFTYSVGGYOXFRQ-UHFFFAOYSA-N dodecane-1,12-diamine Chemical compound NCCCCCCCCCCCCN QFTYSVGGYOXFRQ-UHFFFAOYSA-N 0.000 description 5
150000008134 glucuronides Chemical class 0.000 description 5
210000003405 ileum Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
210000002429 large intestine Anatomy 0.000 description 5
VHRYZQNGTZXDNX-UHFFFAOYSA-N methacryloyl chloride Chemical compound CC(=C)C(Cl)=O VHRYZQNGTZXDNX-UHFFFAOYSA-N 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
LKVFCSWBKOVHAH-UHFFFAOYSA-N 4-Ethoxyphenol Chemical compound CCOC1=CC=C(O)C=C1 LKVFCSWBKOVHAH-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
206010012735 Diarrhoea Diseases 0.000 description 4
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
230000001476 alcoholic effect Effects 0.000 description 4
230000003444 anaesthetic effect Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
125000000751 azo group Chemical group [*]N=N[*] 0.000 description 4
230000000975 bioactive effect Effects 0.000 description 4
150000004985 diamines Chemical class 0.000 description 4
238000007922 dissolution test Methods 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
229930182470 glycoside Natural products 0.000 description 4
150000002338 glycosides Chemical class 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000005457 ice water Substances 0.000 description 4
QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 4
229960004110 olsalazine Drugs 0.000 description 4
239000002245 particle Substances 0.000 description 4
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000003812 trophozoite Anatomy 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010009900 Colitis ulcerative Diseases 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
201000006704 Ulcerative Colitis Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 3
229960004369 flufenamic acid Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
239000008141 laxative Substances 0.000 description 3
230000002475 laxative effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
229960005297 nalmefene Drugs 0.000 description 3
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 3
229960004127 naloxone Drugs 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
230000002351 pectolytic effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
229930186851 sennoside Natural products 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
229960002211 sulfapyridine Drugs 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
BJFIDCADFRDPIO-DZCXQCEKSA-N (2S)-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentazacycloeicos-4-yl]-oxomethyl]-2-pyrrolidinecarboxamide Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1 BJFIDCADFRDPIO-DZCXQCEKSA-N 0.000 description 2
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
JNVGBRQYZHTBTP-UHFFFAOYSA-N 5-[(4-carboxyphenyl)diazenyl]-2-hydroxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N=NC1=CC=C(O)C(C(O)=O)=C1 JNVGBRQYZHTBTP-UHFFFAOYSA-N 0.000 description 2
IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241000224432 Entamoeba histolytica Species 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
108010048179 Lypressin Proteins 0.000 description 2
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
238000005576 amination reaction Methods 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
235000012538 ammonium bicarbonate Nutrition 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
150000004056 anthraquinones Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008953 bacterial degradation Effects 0.000 description 2
AVJBPWGFOQAPRH-MMPMEFKSSA-N beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 AVJBPWGFOQAPRH-MMPMEFKSSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 description 2
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
229960003837 lypressin Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
238000007427 paired t-test Methods 0.000 description 2
LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical class O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
238000005070 sampling Methods 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
229910052712 strontium Inorganic materials 0.000 description 2
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
MUVQKFGNPGZBII-UHFFFAOYSA-N 1-anthrol Chemical class C1=CC=C2C=C3C(O)=CC=CC3=CC2=C1 MUVQKFGNPGZBII-UHFFFAOYSA-N 0.000 description 1
YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
102000009133 Arylsulfatases Human genes 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000606125 Bacteroides Species 0.000 description 1
241001135228 Bacteroides ovatus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000819038 Chichester Species 0.000 description 1
108010026719 Chondroitin Lyases Proteins 0.000 description 1
102000018963 Chondroitin Lyases Human genes 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
235000003805 Musa ABB Group Nutrition 0.000 description 1
240000008790 Musa x paradisiaca Species 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
229930182474 N-glycoside Natural products 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
206010030302 Oliguria Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
235000015266 Plantago major Nutrition 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
241000452413 Sabra Species 0.000 description 1
238000003436 Schotten-Baumann reaction Methods 0.000 description 1
239000009701 Senna Extract Substances 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
241001342522 Vampyrum spectrum Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
150000001454 anthracenes Chemical class 0.000 description 1
230000000398 anti-amebic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
229920013641 bioerodible polymer Polymers 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
AWKDEEXFAVIGAF-UHFFFAOYSA-N bis(4-ethenylphenyl)diazene Chemical compound C1=CC(C=C)=CC=C1N=NC1=CC=C(C=C)C=C1 AWKDEEXFAVIGAF-UHFFFAOYSA-N 0.000 description 1
229960000503 bisacodyl Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
ZYFYTWZIMOACBS-UHFFFAOYSA-N butan-1-ol;ethanol;hydrate Chemical compound O.CCO.CCCCO ZYFYTWZIMOACBS-UHFFFAOYSA-N 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003844 drug implant Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
229940007078 entamoeba histolytica Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229940116333 ethyl lactate Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000005176 gastrointestinal motility Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
150000002341 glycosylamines Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229910001510 metal chloride Inorganic materials 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
210000003249 myenteric plexus Anatomy 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000011224 negative regulation of urine volume Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
229960004570 oxprenolol Drugs 0.000 description 1
PLIKAWJENQZMHA-UHFFFAOYSA-N p-hydroxyphenylamine Natural products NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000005192 partition Methods 0.000 description 1
229920003175 pectinic acid Polymers 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
239000013047 polymeric layer Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
244000144977 poultry Species 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940124513 senna glycoside Drugs 0.000 description 1
IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
150000004666 short chain fatty acids Chemical class 0.000 description 1
235000021391 short chain fatty acids Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000009718 spray deposition Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
108060007951 sulfatase Proteins 0.000 description 1
URNFTLVCQLRCMN-UHFFFAOYSA-N sulisatin Chemical compound CC1=CC=CC2=C1NC(=O)C2(C=1C=CC(OS(O)(=O)=O)=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 URNFTLVCQLRCMN-UHFFFAOYSA-N 0.000 description 1
229950007465 sulisatin Drugs 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
150000004043 trisaccharides Chemical class 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Polymers & Plastics (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Percussion Or Vibration Massage (AREA)
Surgical Instruments (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)
Memory System Of A Hierarchy Structure (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

NO924227A 1990-05-04 1992-11-03 Fremgangsmåte for fremstilling av et kolonisk tilförselssystem NO306096B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51871490A	1990-05-04	1990-05-04
PCT/US1991/003014 WO1991016881A1 (en)	1990-05-04	1991-05-02	Colonic drug delivery system

Publications (3)

Publication Number	Publication Date
NO924227D0 NO924227D0 (no)	1992-11-03
NO924227L NO924227L (no)	1992-12-30
NO306096B1 true NO306096B1 (no)	1999-09-20

Family

ID=24065163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO924227A NO306096B1 (no)	1990-05-04	1992-11-03	Fremgangsmåte for fremstilling av et kolonisk tilförselssystem

Country Status (17)

Country	Link
EP (1)	EP0527942B1 (fi)
JP (1)	JPH05508631A (fi)
KR (1)	KR100194161B1 (fi)
AT (1)	ATE185267T1 (fi)
AU (1)	AU660147B2 (fi)
BR (1)	BR9106419A (fi)
CA (1)	CA2082156A1 (fi)
DE (2)	DE527942T1 (fi)
DK (1)	DK0527942T3 (fi)
ES (1)	ES2048133T3 (fi)
FI (1)	FI924984A0 (fi)
GR (2)	GR940300025T1 (fi)
HU (1)	HU210497B (fi)
MC (1)	MC2288A1 (fi)
NO (1)	NO306096B1 (fi)
RU (1)	RU2113221C1 (fi)
WO (1)	WO1991016881A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4209160A1 (de) *	1992-03-20	1993-09-30	Bauer Kurt Heinz Prof Dr	Vernetzte Polysaccharide, Verfahren zu ihrer Herstellung und ihre Verwendung
US5656290A (en) *	1993-02-26	1997-08-12	The Procter & Gamble Company	Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
AU695906B2 (en) *	1993-11-17	1998-08-27	Commonwealth Scientific And Industrial Research Organisation	Fatty acid delivery system
EP0730447B1 (en) *	1993-11-17	2002-02-20	Commonwealth Scientific And Industrial Research Organisation	Fatty acid delivery system
DE4340057A1 (de) *	1993-11-24	1995-06-01	Falk Pharma Gmbh	Budesonid-Arzneimittel zur Verbesserung der enteralen Flüssigkeitsresorption, insbesondere nach postoperativen Zuständen
ATE226090T1 (de)	1994-04-22	2002-11-15	Yamanouchi Pharma Co Ltd	Kolon-spezifisches arzneistofffreisetzungssystem
US5849327A (en) *	1994-07-29	1998-12-15	Advanced Polymer Systems, Inc.	Delivery of drugs to the lower gastrointestinal tract
US5811388A (en) *	1995-06-07	1998-09-22	Cibus Pharmaceutical, Inc.	Delivery of drugs to the lower GI tract
US5656294A (en) *	1995-06-07	1997-08-12	Cibus Pharmaceutical, Inc.	Colonic delivery of drugs
GB9516268D0 (en)	1995-08-08	1995-10-11	Danbiosyst Uk	Compositiion for enhanced uptake of polar drugs from the colon
CA2244421A1 (en) *	1996-01-16	1997-07-24	Advanced Polymer Systems, Inc.	Topical delivery of drugs to the lower gastrointestinal tract
FR2752843B1 (fr) *	1996-08-30	1998-10-16	Sod Conseils Rech Applic	Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
AU5775398A (en) *	1996-12-17	1998-07-15	Poli Industria Chimica S.P.A.	Site-specific controlled release dosage formulation for mesalamine
US6229009B1 (en)	1997-08-29	2001-05-08	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Polycarboxylic based cross-linked copolymers
AU2484399A (en)	1998-01-30	1999-08-16	Scios Inc.	Controlled release delivery of peptide or protein
KR20000011247A (ko) *	1998-07-23	2000-02-25	김윤	다당류를이용한대장선택성약물전달조성물및약학제제
IT1303738B1 (it) *	1998-11-11	2001-02-23	Aquisitio S P A	Processo di reticolazione di polisaccaridi carbossilati.
IT1303735B1 (it) *	1998-11-11	2001-02-23	Falorni Italia Farmaceutici S	Acidi ialuronici reticolati e loro usi medici.
ATE314091T1 (de)	1999-06-09	2006-01-15	Mochida Pharm Co Ltd	System für wirkstofffreisetzung im unteren verdauungstrakt
FR2799196B1 (fr) *	1999-10-04	2002-02-08	Sod Conseils Rech Applic	Copolymeres reticules a base de copolymeres polycarboxyliques non reticules
CN1744827B (zh) *	2003-01-31	2010-05-26	帝斯曼知识产权资产管理有限公司	包含类胡萝卜素的新颖的组合物
US7670624B2 (en)	2004-01-29	2010-03-02	Astella Pharma Inc.	Gastrointestinal-specific multiple drug release system
GB0607534D0 (en) *	2006-04-13	2006-05-24	Univ London Pharmacy	Colonic drug delivery formulation
KR101122845B1 (ko)	2009-07-30	2012-03-21	부산대학교 산학협력단	경구용 염증성 장질환 치료제
WO2013148258A1 (en)	2012-03-29	2013-10-03	Jerome Schentag	Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
RU2015140610A (ru)	2013-03-14	2017-04-17	ТЕРАБАЙОМ, ЭлЭлСи	Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
ES2938482T3 (es)	2015-01-16	2023-04-11	Seikagaku Kogyo Co Ltd	Sulfato de condroitina reticulado, composición que contiene el mismo y agente de tratamiento para enfermedad ocular

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7504049L (sv) *	1975-04-09	1976-10-10	Haessle Ab	Colonpreparation
DE2717707C3 (de) *	1977-04-21	1979-11-22	Chephasaar Chemisch-Pharmazeutische Fabrik Gmbh, 6670 St Ingbert	Karamellisierte Lactulose
US4668517A (en) *	1985-04-04	1987-05-26	Norwich Eaton Pharmaceuticals, Inc.	Furazolidone dosage form
ZA881301B (en) *	1987-02-27	1989-10-25	Lilly Co Eli	Sustained release matrix formulations
DK110188D0 (da) *	1988-03-02	1988-03-02	Claus Selch Larsen	High molecular weight prodrug derivatives of antiinflammatory drugs
US4857331A (en) *	1988-03-31	1989-08-15	Warner-Lambert Company	Sugarless pectin delivery system
IT1219942B (it) *	1988-05-13	1990-05-24	Fidia Farmaceutici	Esteri polisaccaridici
DE4006521A1 (de) *	1990-03-02	1991-09-05	Bayer Ag	Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen

1991
- 1991-05-02 MC MC91@@D patent/MC2288A1/xx unknown
- 1991-05-02 AU AU80877/91A patent/AU660147B2/en not_active Ceased
- 1991-05-02 ES ES91910743T patent/ES2048133T3/es not_active Expired - Lifetime
- 1991-05-02 HU HU9203451A patent/HU210497B/hu not_active IP Right Cessation
- 1991-05-02 WO PCT/US1991/003014 patent/WO1991016881A1/en not_active Application Discontinuation
- 1991-05-02 BR BR919106419A patent/BR9106419A/pt not_active Application Discontinuation
- 1991-05-02 AT AT91910743T patent/ATE185267T1/de not_active IP Right Cessation
- 1991-05-02 EP EP91910743A patent/EP0527942B1/en not_active Revoked
- 1991-05-02 CA CA002082156A patent/CA2082156A1/en not_active Abandoned
- 1991-05-02 DK DK91910743T patent/DK0527942T3/da active
- 1991-05-02 DE DE91910743T patent/DE527942T1/de active Pending
- 1991-05-02 DE DE69131688T patent/DE69131688T2/de not_active Revoked
- 1991-05-02 JP JP91510595A patent/JPH05508631A/ja active Pending
- 1991-05-02 RU SU92016384A patent/RU2113221C1/ru active
1992
- 1992-11-03 NO NO924227A patent/NO306096B1/no not_active IP Right Cessation
- 1992-11-04 FI FI924984A patent/FI924984A0/fi unknown
- 1992-11-04 KR KR1019920702750A patent/KR100194161B1/ko not_active Expired - Fee Related
1994
- 1994-05-31 GR GR940300025T patent/GR940300025T1/el unknown
1999
- 1999-11-18 GR GR990403000T patent/GR3031906T3/el unknown

Also Published As

Publication number	Publication date
BR9106419A (pt)	1993-05-04
KR100194161B1 (ko)	1999-06-15
NO924227L (no)	1992-12-30
RU2113221C1 (ru)	1998-06-20
HU210497B (en)	1995-04-28
CA2082156A1 (en)	1991-11-05
JPH05508631A (ja)	1993-12-02
AU8087791A (en)	1991-11-27
HUT64210A (en)	1993-12-28
FI924984L (fi)	1992-11-04
EP0527942A4 (en)	1993-10-13
ES2048133T3 (es)	2000-01-16
DE527942T1 (de)	1994-03-03
EP0527942B1 (en)	1999-10-06
GR3031906T3 (en)	2000-02-29
ATE185267T1 (de)	1999-10-15
HU9203451D0 (en)	1993-05-28
AU660147B2 (en)	1995-06-15
DK0527942T3 (da)	2000-03-27
DE69131688T2 (de)	2000-05-25
FI924984A0 (fi)	1992-11-04
WO1991016881A1 (en)	1991-11-14
NO924227D0 (no)	1992-11-03
DE69131688D1 (de)	1999-11-11
ES2048133T1 (es)	1994-03-16
EP0527942A1 (en)	1993-02-24
GR940300025T1 (fi)	1994-05-31
MC2288A1 (fr)	1993-07-14

Publication	Publication Date	Title
NO306096B1 (no)	1999-09-20	Fremgangsmåte for fremstilling av et kolonisk tilförselssystem
US5525634A (en)	1996-06-11	Colonic drug delivery system
Rubinstein	1995	Approaches and opportunities in colon-specific drug delivery
Maroni et al.	2013	Film coatings for oral colon delivery
Patel et al.	2011	Colon targeted drug delivery system: a review system
Qureshi et al.	2013	Colon targeted drug delivery system: A review on current approaches
JP2000503316A (ja)	2000-03-21	胃腸の薬物送達システム
JP2001519379A (ja)	2001-10-23	遅延性総放出胃腸薬物送達システム
Ratnaparkhi Mukesh et al.	2013	Colon targeted drug delivery system
US5352682A (en)	1994-10-04	Compositions containing salts of bile acid-aminosalicylate conjugates
Reddy et al.	2013	Colon targeted drug delivery system: a review
CN101229225A (zh)	2008-07-30	丹参总酚酸胃滞留制剂
Bashardoust et al.	2013	Physicochemical characterization and dissolution study of ibuprofen compression-coated tablets using locust bean gum
Simi et al.	2010	Formulation and evaluation of Albendazole microcapsules for colon delivery using chitosan
Vibhooti et al.	2013	Eudragit and chitosan—The two most promising polymers for colon drug delivery
Kandekar et al.	2022	Fenugreek: Novel delivery technologies and versatile formulation excipients
Purkar et al.	2018	A review on colonic drug delivery system
Parameshwar et al.	2017	Design and development of oral dosage form for colon specific drug release of indomethacine
Nadler Milabuer et al.	2010	Orally administered drug delivery systems to the colon
Bashardoust	2010	Formulation and evaluation of compression coated tablet of ibuprofen for colon specific drug delivery
Ilango et al.	2012	Investigation of colon specificity of novel polysaccharide okra mucilage-film coated with enteric materials
Sharma et al.	2017	Various Approaches Used For Colonic Drug Delivery System
Patel et al.	2022	Colon targeted drug delivery systems: Based on Polymers.
CN119033796A (zh)	2024-11-29	一种人参皂苷Rg3载药系统及其制备方法和应用
Soni et al.	2015	Enzyme specific drug delivery system: a potential approach for colon targeting

Legal Events

Date	Code	Title	Description
2002-01-02	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN NOVEMBER 2001